India · Delayed Price · Currency is INR Panacea Biotec Statistics
Total Valuation
Panacea Biotec has a market cap or net worth of INR 25.18 billion. The enterprise value is 24.61 billion.
| Market Cap | 25.18B |
| Enterprise Value | 24.61B |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 61.25M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -6.88% |
| Owned by Insiders (%) | 68.70% |
| Owned by Institutions (%) | 0.16% |
| Float | 15.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 150.96 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 8.18 |
| Debt / FCF | -0.63 |
| Interest Coverage | -4.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -3.90% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.13M |
| Profits Per Employee | -33,132 |
| Employee Count | 2,149 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.01% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -0.01% |
| 50-Day Moving Average | 485.49 |
| 200-Day Moving Average | 401.37 |
| Relative Strength Index (RSI) | 40.34 |
| Average Volume (20 Days) | 10,319 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Panacea Biotec had revenue of INR 6.73 billion and -71.20 million in losses. Loss per share was -1.17.
| Revenue | 6.73B |
| Gross Profit | 3.68B |
| Operating Income | -303.80M |
| Pretax Income | -103.60M |
| Net Income | -71.20M |
| EBITDA | 28.92M |
| EBIT | -303.80M |
| Loss Per Share | -1.17 |
Balance Sheet
The company has 744.00 million in cash and 236.60 million in debt, with a net cash position of 507.40 million.
| Cash & Cash Equivalents | 744.00M |
| Total Debt | 236.60M |
| Net Cash | 507.40M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.29B |
| Book Value Per Share | 128.44 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 166.80 million and capital expenditures -540.90 million, giving a free cash flow of -374.10 million.
| Operating Cash Flow | 166.80M |
| Capital Expenditures | -540.90M |
| Depreciation & Amortization | 332.72M |
| Net Borrowing | n/a |
| Free Cash Flow | -374.10M |
| FCF Per Share | n/a |
Margins
Gross margin is 54.66%, with operating and profit margins of -4.52% and -1.06%.
| Gross Margin | 54.66% |
| Operating Margin | -4.52% |
| Pretax Margin | -1.54% |
| Profit Margin | -1.06% |
| EBITDA Margin | 0.43% |
| EBIT Margin | -4.52% |
| FCF Margin | n/a |
Dividends & Yields
Panacea Biotec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.61% |
| Shareholder Yield | 0.61% |
| Earnings Yield | -0.28% |
| FCF Yield | -1.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |